Valuation: Abbott Laboratories (Pakistan) Limited

Market Cap 93.11B 335M 293M 271M 249M 470M 32.31B 481M 3.21B 1.27B 15.8B 1.26B 1.23B 54.51B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 93.11B 335M 293M 271M 249M 470M 32.31B 481M 3.21B 1.27B 15.8B 1.26B 1.23B 54.51B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
19.95%
Yield 2024 *
-
Yield 2025 3.81%
1 day-2.03%
1 week-1.42%
Current month-3.38%
1 month+0.31%
3 months-2.60%
6 months-21.44%
Current year-9.43%
1 week 920.01
Extreme 920.01
980
1 month 920.01
Extreme 920.01
1,029
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,304
3 years 330
Extreme 330
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 01/04/2016
Director of Finance/CFO - 01/11/2019
Chief Operating Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member - 01/03/2009
Director/Board Member - 04/06/2014
Chairman - 30/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-1.42%-13.50%+131.94% 342M
+0.85%-3.11%+49.29%+162.34% 1,043B
+1.23%-2.34%+53.56%+58.28% 602B
+0.04%+1.83%+33.53%+87.11% 449B
+0.78%-0.39%+30.44%+23.23% 327B
+1.41%+0.56%+31.41%+47.13% 279B
-0.27%-5.69%+20.68%+21.99% 264B
-1.42%+0.73%+22.50%+61.06% 201B
-1.48%-0.42%+22.24%+73.96% 169B
-0.36%+3.30%+1.79%-31.03% 143B
Average -0.29%-0.61%+25.19%+63.60% 347.74B
Weighted average by Cap. -0.05%-1.82%+37.79%+83.51%

Financials

2024 2025
Net sales 68.18B 246M 215M 198M 182M 344M 23.66B 352M 2.35B 930M 11.57B 922M 902M 39.91B 75.4B 272M 237M 219M 202M 381M 26.16B 389M 2.6B 1.03B 12.8B 1.02B 997M 44.14B
Net income 5.23B 18.85M 16.47M 15.21M 14.01M 26.43M 1.82B 27.02M 181M 71.41M 888M 70.79M 69.23M 3.06B 7.97B 28.69M 25.07M 23.15M 21.32M 40.22M 2.76B 41.13M 275M 109M 1.35B 108M 105M 4.66B
Net Debt - -
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
17/07/26 PKR 951.11 -2.03% 11,794
16/07/26 PKR 970.80 +4.29% 71,748
15/07/26 PKR 930.91 +0.46% 7,755
14/07/26 PKR 926.63 -2.50% 14,501
13/07/26 PKR 950.35 -1.36% 48,683
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
951.11
Average target price
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABOT Stock